When was Ollin founded?

Ollin was founded in 2023 and raised its 1st funding round 2 years after it was founded.

Where is Ollin located?

Ollin is headquartered in Austin, United States.

How many employees does Ollin have?

As of Jun 30, 2026, the latest employee count at Ollin is 23.

Is Ollin a funded company?

Ollin is a funded company, having raised a total of $430M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Sep 17, 2025.

When was the latest funding round of Ollin?

Ollin's latest funding was a $***** Series B round on May 14, 2026, with participation from 10 investors. Its primary sector is Ophthalmology. In United States, the Ophthalmology sector has seen $1.37B in funding in 2026 to date.

Where does Ollin rank among its competitors?

Ollin ranks 718th amongst 2658 active competitors, of which 902 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Ollin?

Ollin's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Ollin - 2026 Company Profile, Funding & Competitors

Company Details

Clinical-stage biopharmaceutical company focused on developing innovative therapies for ophthalmic diseases. The company leverages its expertise in ophthalmology drug development to bring promising treatments to market. Ollin Biosciences is dedicated to acquiring and developing best-in-disease therapies.

Website: ollin.bio
Social
Email ID: *****@ollin.bio

Key Metrics

Founded Year

2023

Location

Austin, United States

Stage

Series B

Total Funding

$430M in 2 rounds

Latest Funding Round

Series B, May 14, 2026, $*****

Investors

Arch Venture Partners & 9 more

Ranked

718^th among 2658 active competitors

Employee Count

23 as on Jun 30, 2026

Similar Companies

Viridian Therapeutics & 290 more

View Ollin's full profile

Ollin has raised a total funding of $430M over 2 rounds. Its first funding round was on Sep 17, 2025. Its latest funding round was a Series B round on May 14, 2026 for $*****. 10 investors participated in its latest round. Ollin has 10 institutional investors.

Here is the list of recent funding rounds of Ollin:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 14, 2026	9260470	Series B	1249787	6187010	9158334	4308854
Sep 17, 2025	7521245	Series A	2742311	5731375	Arch Venture Partners	Mubadala Capital & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of Ollin's funding rounds and investors

Ollin's employee count trend

Ollin has 23 employees as of Jun 26. Here is Ollin's employee count trend over the years:

Uncover Ollin's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Ollin include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Ollin, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 18 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
6th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
7th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
8th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
9th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100
10th	Celularity 2016, Warren (United States), Public	Developer of allogeneic cell therapies to treat multiple diseases	$290M	Celgene, Dreyfus Family Office & 8 others	71/100
718th	Ollin 2023, Austin (United States), Series B	Clinical-stage biopharmaceutical company focused on developing innovative therapies for ophthalmic diseases	$430M	T. Rowe Price, Commodore Capital & 8 others	43/100